Medicare part d premium stabilization program to end early, impacting beneficiaries

The Centers for Medicare & Medicaid Services (CMS) revealed on July 30, 2026, its plan to conclude the Part D Premium Stabilization Demonstration by the end of 2026, ceasing the program earlier than its intended sunset [Medicare Rights Center]. This program was designed to help control premium increases for stand-alone prescription drug plans (PDPs) as changes introduced by the Inflation Reduction Act (IRA) took effect [Medicare Rights Center].

Understanding the Impact on Premiums

The Inflation Reduction Act (IRA) restructured Medicare Part D, introducing a crucial out-of-pocket spending cap for enrollees, which is $2,100 in 2026 [Medicare Rights Center]. While this cap offers significant financial protection to beneficiaries, it also shifted some cost responsibilities onto the Part D plans themselves. In response to these new cost liabilities, many plans proposed higher premiums [Medicare Rights Center].

The Part D Premium Stabilization Demonstration was implemented to mitigate the impact of these rising costs on beneficiaries. Its early termination means that individuals enrolled in stand-alone Part D plans may face steeper premium increases in 2027 than they would have otherwise [Medicare Rights Center].

The Discrepancy Between Plan Types

Medicare Advantage plans that include Part D (MA-PDs) may not experience the same pressure to raise premiums as stand-alone PDPs. According to the Medicare Rights Center, MA-PDs have more flexibility to absorb increased costs, potentially through existing Medicare funding mechanisms and other overpayments [Medicare Rights Center]. This creates a disparity where MA-PDs can offer lower drug plan rates, potentially drawing beneficiaries away from Original Medicare with a stand-alone Part D plan, even if an MA plan isn't the best choice for their overall healthcare needs [Medicare Rights Center].

Medicare Rights Center emphasizes that choosing between Original Medicare and Medicare Advantage is a complex and personal decision. They argue that imbalances in how premiums are set can distort this decision-making process, possibly leading beneficiaries to choose plans based purely on drug costs rather than comprehensive health considerations [Medicare Rights Center].

What This Means for You

As the Part D Premium Stabilization Demonstration winds down, it is important for Medicare beneficiaries to carefully review their prescription drug coverage options for 2027. If you are currently enrolled in a stand-alone Part D plan, prepare for the possibility of higher premiums. Consider comparing available plans during the annual enrollment period, typically in the fall, to find coverage that best fits your medical and financial needs. Evaluating both stand-alone Part D plans and Medicare Advantage plans with prescription drug coverage will be crucial to ensure you make an informed decision for your healthcare.